ArticleResearch square2026
The development of Breast Apocrine Carcinoma (BAC) score that distinguishes breast and cutaneous apocrine carcinomas.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Background: Apocrine carcinoma (AC) is a rare cancer that arises either from cutaneous apocrine sweat glands (cutaneous AC) or as breast carcinoma with apocrine differentiation (breast AC). Differentiation between them is clinically critical because their management and outcomes differ significantly: breast AC is treated according to established breast cancer therapies, whereas cutaneous AC lacks standardized systemic treatment and often carries a poorer prognosis. A diagnostic challenge arises when AC occurs in the axilla, where both entities may arise, given their highly similar histology. Methods: In this study, we performed a retrospective multi-cohort transcriptomic analysis integrating institutional, multi-institutional, and publicly available datasets to characterize the molecular differences between breast and cutaneous AC, and developed a transcriptomic classifier using differentially expressed genes and a LASSO logistic regression model for tissue-of-origin classification. Results: Transcriptomic profiling revealed that breast ACs exhibited higher steroid hormone-related signaling and lower proliferative activity compared with cutaneous ACs, while immune-related features were largely comparable between the two tumor types. These findings suggest that, despite shared apocrine morphology, breast and cutaneous ACs retain distinct biological characteristics reflective of their tissue of origin. Building on this, we further developed a transcriptomic classifier, the Breast Apocrine Carcinoma (BAC) score, which accurately distinguished breast and cutaneous ACs, suggesting that these tumors retain distinct tissue-of-origin transcriptional signatures despite shared apocrine differentiation. Furthermore, application of the BAC score to tumors with unknown primary origin in the axillary region enabled estimation of tissue origin, highlighting its potential clinical utility in diagnostically challenging cases. Conclusion: Breast and cutaneous ACs exhibit distinct biological features despite shared apocrine morphology. The BAC score accurately distinguished tumors of breast and cutaneous origin, including within AC cohorts, highlighting the potential utility of transcriptomic profiling for improving their classification and diagnostic evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.